Market Overview

Novartis Skin Cancer Drug Combination Involving Spartalizumab Fails Clinical Trial

Share:
Novartis Skin Cancer Drug Combination Involving Spartalizumab Fails Clinical Trial

Swiss pharmaceutical company Novartis AG (NYSE: NVS) announced Saturday that the phase three COMBI-i trial for a combination of drugs against a type of advanced skin cancer didn't meet the clinical requirements of the evaluation.

What Happened: The study was a randomized, double-blind, placebo-controlled trial using Spartalizumab — an investigational monoclonal antibody, alongside Tafinlar and Mekinist.

The company reported that the drug combination was tested on untreated Stage IIIC and Stage IV BRAF V600 mutation-positive cutaneous melanoma patients, but it didn't enhance the progression-free survival.

The evaluation was conducted in three parts and the declared results were from the final stages of testing, Novartis said.

Why It Matters:  The company noted it intended to continue Spartalizumab development, despite negative clinical trial results.

“While the COMBI-i trial did not reach its primary endpoint, the study’s findings give us valuable insights into the role the investigational immunotherapy spartalizumab may play in future cancer therapy combinations and underscore the previously established importance of Tafinlar [and] Mekinist for these patients,” Novartis Chief Medical Officer John Tsai said in a statement.

Novartis-backed Poseida Therapeutics (NASDAQ: PSTX) also announced last week it had halted its prostate cancer drug trial after a patient's death.

Price Action: Novartis shares closed 0.85% lower at $86.40 on Friday. The stock gained 0.09% during extended trading hours, the same day.

 

Related Articles (NVS)

View Comments and Join the Discussion!

Posted-In: clinical trials SpartalizumabBiotech News Health Care Events General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com